GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (LSE:OXB) » Definitions » Retained Earnings

Oxford BioMedica (LSE:OXB) Retained Earnings : £-352.92 Mil (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Oxford BioMedica Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Oxford BioMedica's retained earnings for the quarter that ended in Dec. 2023 was £-352.92 Mil.

Oxford BioMedica's quarterly retained earnings declined from Dec. 2022 (£-198.55 Mil) to Jun. 2023 (£-244.43 Mil) and declined from Jun. 2023 (£-244.43 Mil) to Dec. 2023 (£-352.92 Mil).

Oxford BioMedica's annual retained earnings declined from Dec. 2021 (£-165.81 Mil) to Dec. 2022 (£-198.55 Mil) and declined from Dec. 2022 (£-198.55 Mil) to Dec. 2023 (£-352.92 Mil).


Oxford BioMedica Retained Earnings Historical Data

The historical data trend for Oxford BioMedica's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica Retained Earnings Chart

Oxford BioMedica Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -187.70 -188.72 -165.81 -198.55 -352.92

Oxford BioMedica Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -165.81 -178.06 -198.55 -244.43 -352.92

Oxford BioMedica Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Oxford BioMedica  (LSE:OXB) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Oxford BioMedica (LSE:OXB) Business Description

Traded in Other Exchanges
Address
Windrush Court, Transport Way, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.

Oxford BioMedica (LSE:OXB) Headlines

No Headlines